Abstract 1561P
Background
The aim of the study was to know changes of muscle mass, muscle strength and fatigue symptom scale during three cycles of chemotherapy in adult women breast cancer.
Methods
A prospective cohort study underwent in the cancer referral hospital in Tangerang, Banten, Indonesia. Adult women breast cancer patients who will undergo chemotherapy after diagnosed will be included to the study. Evaluation of muscle mass and strength were using Bio-impedance analysis and JAMAR hand grip strength evaluation, respectively The cut off of low muscle mass and strength were using the mean of Indonesian healthy population muscle mass and strength minus 2 standards of deviation. The evaluation of fatigue using breast cancer quality of life questionnaire QLQ-C30 and BRE-23. Diet and exercise activities were also evaluated during chemotherapy. Patients were followed up until 3 cycle of chemotherapy. Muscle mass, muscle strength and fatigue symptom were evaluated 1 week before the next cycle schedule of chemotherapy. Independent T test or Mann Whitney statistical analysis were used the evaluation.
Results
Eighty-six subjects were included to the study with mean of age 46.7±7.71 years old. More than half subject with overweight-obese category. Fifty-one (59.3%) subjects were using Taxan based chemotherapy. The mean of muscle mass and strength were 6.41±0.96 and 20.38±4.82, respectively. The median of fatigue score from symptom scale of QLQ-C30 was 22.85(0-23). The mean of muscle mass after chemotherapy cycle one to three were 6.04±0.76, 5.97±0.75, and 5.50±0.70, respectively. The mean of muscle strength after chemotherapy cycle one to three were 18.33±6.02, 17.59±4.69, and 15.29±4.47, respectively. The decreased of muscle mass and strength were statistically significant compared to not decreased group. Four and six subjects became sarcopenia after chemotherapy cycle 1 and 3, respectively. The median of fatigue scale was decreased to 17.9 (0-18) after three cycle of chemotherapy.
Conclusions
Muscle mass and strength were decreased proportionally during three cycles of chemotherapy. However, the symptoms scale of fatigue also decreased after 3 cycles of chemotherapy. Further research needs to be done to explore this field.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.